Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Randomized, Two-Period, Two-Treatment, Two-Sequence, Single Dose, Crossover Study to Evaluate the Safety and Pharmacokinetics of Oral and Intravenous Administration of Methamphetamine Hydrochloride in Healthy Volunteers

Next Previous
X
Search
Trial Profile

A Phase 1, Open-Label, Randomized, Two-Period, Two-Treatment, Two-Sequence, Single Dose, Crossover Study to Evaluate the Safety and Pharmacokinetics of Oral and Intravenous Administration of Methamphetamine Hydrochloride in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 12 Jul 2011

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Metamfetamine (Primary) ; Metamfetamine (Primary)
  • Indications Brain injuries; Stroke
  • Focus Adverse reactions

    • Most Recent Events

    • 12 Jul 2011 Status changed from recruiting to completed.
    • 11 Jul 2011 Added title (from MR) and treatment table. Amended purpose.
    • 14 Jun 2010 Status changed from planning to recruiting, based on a Sinapis Pharma media release. Dosing in the first cohort has been successful; future cohorts will investigate longer infusion times and higher dosages.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top